Patents by Inventor Omer Rizwan SIDDIQUI

Omer Rizwan SIDDIQUI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USE OF ANTI-SORTILIN ANTIBODIES
    Publication number: 20240132597
    Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured or humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.
    Type: Application
    Filed: December 7, 2023
    Publication date: April 25, 2024
    Applicant: Alector LLC
    Inventors: Robert PAUL, Sam JACKSON, Omer Rizwan SIDDIQUI, Michael F. WARD, Felix Leejia YEH, Julie Y. HUANG, Whedy WANG, Yijie LIAO, Brian C. MANGAL
  • METHODS OF USE OF ANTI-TREM2 ANTIBODIES
    Publication number: 20230183341
    Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a TREM2 protein, e.g., human TREM2, for use in treating and/or delaying progression of a disease or injury in an individual in need thereof.
    Type: Application
    Filed: April 2, 2021
    Publication date: June 15, 2023
    Applicant: Alector LLC
    Inventors: Robert PAUL, Michael F. WARD, Hua LONG, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL, Felix Leejia YEH, Sam JACKSON
  • METHODS OF USE OF ANTI-CD33 ANTIBODIES
    Publication number: 20230035072
    Abstract: The present disclosure is generally directed to antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics. The present disclosure is further directed to the methods of treating and/or delaying the progression of a disease or injury in an individual by administering such antibodies.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 2, 2023
    Applicant: Alector LLC
    Inventors: Robert PAUL, Michael F. WARD, Hua LONG, Shiao-Ping LU, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL
  • METHODS OF USE OF ANTI-SORTILIN ANTIBODIES
    Publication number: 20200392229
    Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.
    Type: Application
    Filed: June 10, 2020
    Publication date: December 17, 2020
    Applicant: Alector LLC
    Inventors: Robert PAUL, Michael F. WARD, Hua LONG, Shiao-Ping LU, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL, Herve RHINN